Description: IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies. Established in 2003, the Montreal-based company, listed on the TSX-V and OTC-QX, develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilmTM, VersaTabTM and AdVersaTM. IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XLTM, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilmTM technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
Home Page: www.intelgenx.com
6420 Abrams
Montreal,
QC
H4S 1Y2
Canada
Phone:
514 331 7440
Officers
| Name | Title |
|---|---|
| Dr. Horst G. Zerbe Ph.D. | Chairman, CEO & Chairman of Scientific Advisory Board |
| Mr. André Godin C.A., CPA, CA, CPA | Pres & CFO |
| Mr. Tommy Kenny J.D., L.L.B., M.Sc. | VP of Intellectual Property & Legal Affairs and Gen. Counsel |
| Ms. Nadine Paiement | Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp |
| Stephen Kilmer | Investor Relations Officer |
| Ms. Ingrid Zerbe | Corp. Sec. |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.5411 |
| Price-to-Sales TTM: | 19.1135 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |